Kappac Pharma Peer Comparison

BSE: 506938

₹112.85

₹-5.90 (-4.97%)

As on 06-Jan-2015IST

Market cap

₹341 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

9

Div. Yield

0 %

Edit

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	341	31,674	26,307	26,224	25,017
Revenue (₹ Cr)	--	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-2.20	414.00	-371.81	387.35	288.22
Net Margin (%)	101.15	11.23	-3.93	26.01	14.79
RoE (%)	-6.25	8.38	-3.85	25.18	29.77
Price to Earnings	--	77.44	--	67.90	86.80
Price-To-Book	8.97	6.29	3.29	15.20	18.64

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	--	4,830.36	--	76.11	41.58
Total Income	0.00	4,914.64	--	76.68	41.73
Total Expenditure	0.08	3,850.53	--	69.99	30.00
EBITDA	-0.08	979.83	--	6.12	11.59
Depreciation	--	139.92	--	0.80	3.35
EBIT	-0.08	839.91	--	5.32	8.24
Interest	0.00	83.35	--	1.58	2.34
Other Income	--	84.28	--	0.56	0.14
Exceptional Items	--	49.83	--	--	--
Profit before Tax	-0.08	890.67	--	4.31	6.04
Provision for Tax	--	47.88	--	1.44	1.54
Profit after Tax	-0.08	842.79	--	2.86	4.50

Liabilities (₹ Cr)

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	38.11	3,581.47	--	10.77	44.83
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	0.00	1,161.18	--	1.29	10.36
Current Liabilities	0.50	1,743.20	--	26.33	21.34
Total Liabilities	38.61	6,622.02	--	38.71	76.53

Assets (₹ Cr)

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	8.31	3,266.10	--	7.38	51.75
Current Assets	30.30	3,355.92	--	31.01	24.78
Total Assets	38.61	6,622.02	--	38.71	76.53
Total Debt*	0.49	1,906.08	--	12.17	21.09
Net Current Assets	29.80	1,612.72	--	4.68	3.44
Contingent Liabilities	--	267.40	--	--	4.70

Cashflow (₹ Cr)

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	4.19	1,476.29	--	-0.21	6.29
Cash Flow from Investing Activities	-5.42	-851.62	--	-2.00	-5.46
Cash from Financing Activities	-4.24	-601.32	--	2.17	-0.58
Net Cash Inflow / Outflow	-0.04	23.35	--	-0.04	0.25

Ratios

Profitability Ratios

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	-0.27	18.98	--	29.97	13.38
ROE (%)	-0.27	30.04	--	30.26	19.08
ROA (%)	-0.26	13.36	--	8.85	6.16
EBIT Margin (%)	--	22.03	--	8.78	28.21
Net Margin (%)	--	17.15	--	3.74	10.78
Cash Profit Margin (%)	--	20.32	--	4.81	18.86

Growth Ratios

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	--	-13.89	--	37.10	12.11
EBIT Growth (%)	-0.28	-49.66	--	30.95	21.82
Net Profit Growth (%)	0.08	-46.64	--	39.55	58.36
EPS Growth (%)	21.43	-56.04	--	39.55	58.36
Book Value Growth (%)	59.47	36.37	--	32.03	21.09

Valuation Ratios

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	6.59	--	0.00	0.00
Price / Book Value	54.69	1.55	--	0.00	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	0.00	5.73	--	2.02	3.52
Market Cap (₹ Cr)	--	5,016.58	--	0.00	0.00

Solvency Ratios

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.01	0.54	--	1.13	0.47
Short term debt to equity ratio	0.01	0.06	--	0.84	0.23
Current Ratio	60.78	1.93	--	1.18	1.16
Quick Ratio	60.78	1.36	--	0.75	1.11
Interest Coverage	-3,866.11	11.69	--	3.73	3.58

Operating Efficiency Ratios

	Kappac Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	--	9.96	--	17.81	33.85
Asset Turnover	0.00	0.77	--	2.35	0.57
Receivable days	--	54.33	--	58.46	106.93
Inventory Days	--	77.43	--	41.85	10.49
Payable days	--	120.43	--	91.25	213.33
Cash Conversion Cycle	--	11.32	--	9.06	-95.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly